HK Stock MarketDetailed Quotes
01167 JACOBIO-B
- 1.690
- +0.090+5.63%
Not Open Apr 26 16:08 CST
1.34BMarket Cap-3373P/E (TTM)
1.700High1.580Low818.40KVolume1.610Open1.600Pre Close1.36MTurnover0.10%Turnover RatioLossP/E (Static)791.76MShares7.77052wk High1.13P/B1.34BFloat Cap1.38052wk Low--Dividend TTM791.76MShs Float25.350Historical High--Dividend LFY7.50%Amplitude1.380Historical Low1.662Avg Price300Lot Size--Div YieldTTM--Div Yield LFY
About JACOBIO-B Company
Garcos Pharmaceutical Group Co., Ltd. is committed to providing patients with breakthrough treatment solutions. The company's vision is to work hand in hand with partners to become a globally recognized leader in drug development. The company's laboratories are located in Beijing, China and Massachusetts, USA, and the experimental platforms have the technology to develop modified inhibitors of protein phosphatase, KRAS, and other transcription factors. Gacos has received investments from several biotechnology-specialized investment institutions, including Qiming Ventures, Lilly Asia Fund, Gao Lin, and Taiwan's Yu Sheng.
Company Profile
Symbol01167
Company NameJACOBIO-B
ISINKYG4987A1094
Listing DateDec 21, 2020
Issue Price14.00
Shares Offered96.48M share(s)
FoundedJun 1, 2018
Registered AddressCayman Islands
Chairmanyinxiang wang
Secretaryqingzhongminghui xue
Audit InstitutionPricewaterhouseCoopers
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeWalkers Corporate Limited, 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands
Head Office and Principal Place of Business40th Floor, Dah Sing Financial Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees301
MarketHong Kong motherboard
Phone(010)56315466
Fax(010)56315314
EmailIR@jacobiopharma.com
Websitehttp://www.jacobiopharma.com
Business Garcos Pharmaceutical Group Co., Ltd. is a Chinese investment holding company mainly engaged in the development of new clinical-stage drugs. The company is mainly responsible for the independent discovery and development of innovative oncology treatments. The company's major drug development projects include JAB-3068 and JAB-3312 clinical-stage modified SHP2 inhibitors. The company mainly operates in the domestic market.
Company Executives
- Name
- Position
- Salary
- yinxiang wang
- CEOs，Chairman，Executive Director，Chairman of the Nomination Committee
- --
- xiaojie wang
- CEO，Executive Director，Remuneration Committee Members，Authorized Representative
- --
- yunyan hu
- senior vice president，Executive Director
- --
- yanmin tang
- Non-executive directors，Nomination Committee Members，Remuneration Committee Members
- --
- deli chen
- Non-executive directors，Audit Committee Members
- --
- ruilin song
- Independent Non-Executive Director，Remuneration Committee Chairman，Nomination Committee Members
- --
- ge wu
- Independent Non-Executive Director，Nomination Committee Members，Remuneration Committee Members，Audit Committee Members
- --
- bai lu
- Independent Non-Executive Director，Chairman of the Audit Committee，Nomination Committee Members，Remuneration Committee Members
- --
- yi wang
- senior vice president，Chief Medical Officer
- --
- qing xue
- Joint Company Secretary
- --
- minghui zhong
- Joint Company Secretary，Authorized Representative
- --
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg